RBC Capital initiated coverage of Perspective Therapeutics with an Outperform rating and $3 price target. Targeted radiopharmaceutical therapy, or TRT, continues to rise through new innovations, investments, deals, and data, with next-gen alphatherapies key to the advancement, says the firm, which believes Perspective is well-positioned in that context. The company has established a unique, decentralized manufacturing network for the delivery of lead-212, or 212Pb, to harness a unique decay profile and therapeutic benefits, adds the firm, which looks toward near-term updates from both VMT-alpha-NET and VMT01 over 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Shopify upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
- Perspective Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Perspective Therapeutics to Participate at Upcoming May Investor Conferences
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
- Perspective Therapeutics selected by FDA to participate in CDRP program